pharmaceuticals

Grifols S.A. (NASDAQ:GRFS), the Barcelona, Spain-based pharmaceutical company, saw its shares plummet by 24% on Tuesday. This marked the company’s most significant single-day drop since its initial public offering. The cause? A bombshell short report released by Gotham City Research that...

Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly marketing as many as five products by 2026. Merck & CO Inc (NYSE: MRK) shares also...

U.S. stock markets gave a mixed picture on Thursday with the Dow Jones inching up 0.03% to 37,440.34. The S&P 500 and Nasdaq fell 0.34% and 0.56% to 4,688.68 and 14,510.30 respectively. These are the top stocks that gained the attention of retail traders and investors throughout the day:...

Drugmaker Eli Lilly And Co (NYSE:LLY) announced on Thursday a new website that allows patients to get a weight loss drug prescription through a telehealth provider. LillyDirect offers disease management resources, including access to independent healthcare providers, tailored support and direct...

U.S. stocks experienced mixed results in Tuesday’s trading session. The Dow Jones index showed resilience, gaining around 25 points, a modest rise of 0.07% to 37,715.04. In contrast, the tech-heavy NASDAQ faced a downturn, falling 1.63% to 14,765.94. Similarly, the S&P 500 also witnessed...

Billionaire businessman Mark Cuban, a vocal critic of Elon Musk‘s management of the social-media platform X, responded to Musk’s inquiry about the anti-parasitic treatment, ivermectin. What happened: A user on the X platform with the handle @MdBreathe questioned Cuban in June about...

Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this memory-robbing disease.  Clinical trials for at least seven Alzheimer's disease...

ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the consensus of $111.92 million. Net revenues for generic pharmaceutical products were $63.7 million, up 29.7%, driven by increased volume from the annualization of 2022...

Perrigo Company PLC (NYSE: PRGO) reported third-quarter sales of $1.12 billion, up 2.2% Y/Y, missing the consensus of $1.20 billion, driven primarily by the acquisition of the Gateway infant formula facility and the U.S. and Canadian Good Start infant formula brand.  The company...

Alpine Immune Sciences Inc (NASDAQ: ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology (ASN) Kidney Week. In IgAN, treatment with low-dose povetacicept, 80 mg SC every four weeks,...

Bristol Myers Squibb (NYSE:BMY) has named Christopher Boerner as their new Chair of the Board of Directors and CEO. Boerner, who is set to take over as Chair in April 2024, will assume the role of CEO from November 1. What Happened: The pharmaceutical giant announced on October 31 that Boerner was...

Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, is now popular for weight loss. The rise of the drug could become a major headwind for other companies that provide weight-loss services such as liposuction and bariatric surgeries. Some companies are already seeing the impact of...

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market.  Along with lovo-cel, Vertex Pharmaceuticals Inc/...

Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical and medical devices businesses. This is the company’s first quarterly report since...

Clene Inc. (NASDAQ: CLNN) released long-term follow-up data for patients treated with CNM-Au8 30mg for up to 133 weeks in the HEALEY ALS Platform Trial.  These post hoc results showed significantly improved survival with a 49% decreased risk of death for the covariate risk-...